- Research works
- 13 ▼ 87% vs 2018-21
- Citations
- 51 3.8 per fractional work
- Top-10% rate
- 2.7% all institutions 10.0%
- Open access
- 14% world 40%
- International
- 6% world 18%
Not ranked overall: Cyteir Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.
Which fields of science does Cyteir Therapeutics (United States) work in?
In all years, 68% of research at Cyteir Therapeutics (United States) is in Life Sciences, 32% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (66%), Medicine (32%), Immunology and Microbiology (2%). It does 2.4× the world's share of Life Sciences.
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Its 3 domains and 4 fields, with their numbers
Who are the top researchers at Cyteir Therapeutics (United States)?
Ranked on the quality score, Melinda A. L. Day and Tyler M. Maclay lead among researchers whose main affiliation is Cyteir Therapeutics (United States).
- 1
Melinda A. L. Day
United States · #1,976,126 worldwide 86 citations · 23 works
- 2
Tyler M. Maclay
United States · #2,352,075 worldwide 35 citations · 16 works
Which research topics does Cyteir Therapeutics (United States) publish most on?
By volume in 2022-now: Cancer, Hypoxia, and Metabolism, RNA Research and Splicing, Metabolomics and Mass Spectrometry Studies and Advanced Breast Cancer Therapies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
- 2 RNA Research and Splicing Molecular Biology 0 works
- 3 Metabolomics and Mass Spectrometry Studies Molecular Biology 0 works
- 4 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works
- 5 Protein Degradation and Inhibitors Molecular Biology 0 works
- 6 14-3-3 protein interactions Molecular Biology 0 works
- 7 Peptidase Inhibition and Analysis Oncology 0 works
- 8 Cancer Treatment and Pharmacology Oncology 0 works
- 9 Colorectal Cancer Treatments and Studies Oncology 0 works
- 10 PARP inhibition in cancer therapy Oncology 0 works
How open and international is its research?
Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 40% of research is openly available.
World: 18% is written across borders.
How has Cyteir Therapeutics (United States)'s research output changed?
Output in 2022-2025 was 87% lower than in 2018-2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Lexington
- Institute for Learning and Development
- Atmospheric and Environmental Research
- Inotek Pharmaceuticals (United States)
- Biostatistical Consulting (United States)
- Cubist Pharmaceuticals (United States)
- Ocean Acoustical Services and Instrumentation Systems (United States)
- Boston Collaborative Drug Surveillance Program
- Synta Pharmaceuticals (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about Cyteir Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.